Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.47 |
| ▸ | AGXT | P21549 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20219407 | 0.94 | TLR7 (0.43) | TLR7TLR8AGXTKCNH2LPAR3 | |
| SCHEMBL20413272 | 0.93 | AGXT (0.43) | TLR7TLR8AGXTLPAR3CRHR1 | |
| SCHEMBL15470137 | 0.90 | TLR7 (0.54) | TLR7TLR8AGXTCYP2D6DRD1 | |
| SCHEMBL13195050 | 0.85 | TLR7 (0.50) | TLR7TLR8AGXTCYP2D6DRD1 | |
| SCHEMBL20219315 | 0.84 | TLR7 (0.66) | TLR7TLR8CYP2D6DRD1HTR2A | |
| SCHEMBL20219310 | 0.83 | TLR7 (0.46) | TLR7TLR8AGXTCYP2D6DRD1 | |
| SCHEMBL15469707 | 0.83 | TLR7 (0.46) | TLR7TLR8AGXTCYP2D6DRD1 | |
| SCHEMBL23472172 | 0.81 | AGXT (0.39) | TLR7TLR8AGXTLPAR3CRHR1 | |
| SCHEMBL20386616 | 0.81 | AGXT (0.39) | TLR7TLR8AGXTLPAR3CRHR1 | |
| SCHEMBL20219313 | 0.80 | TLR7 (0.47) | TLR7TLR8CYP2D6DRD1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-26 | — | — | US | disclosed |
| EP-3330257-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | Janssen Sciences Ireland UC (IE) | 2018-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | TLR7 1000/4885TLR8 1540/4885AGXT 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.